ZyVersa Therapeutics, Inc. (ZVSA)
USD 1.1
(10.0%)
USD 1.1
(10.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Operating Cash Flow | -8.72 Million | -1.49 Million | -5.07 Million | -5.1 Million |
| Net Income | -98.29 Million | -14.04 Million | -8.08 Million | -12.68 Million |
| Depreciation & Amortization | 10.4 Thousand | 9868.00 | 10.4 Thousand | 10.4 Thousand |
| Deferred income taxes | -9.47 Million | -745.05 Thousand | -441.58 Thousand | 333.65 Thousand |
| Stock-based compensation | 1.19 Million | 3.52 Million | 4.14 Million | 3.83 Million |
| Change in working capital | 2.6 Million | 8.29 Million | -1.02 Million | 3.11 Million |
| Other non-cash items | 95.25 Million | 1.47 Million | 317.83 Thousand | 288.36 Thousand |
| Investing Cash Flow | - | - | - | - |
| Investments in PPE | -1.00 | - | - | - |
| Acquisitions | - | - | - | - |
| Investment purchases | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - |
| Other Investing Activities | - | - | - | - |
| Financing Cash Flow | 5.95 Million | 1865.38 | 5.23 Million | 4.56 Million |
| Debt repayment | - | - | -5.23 Million | -1.68 Million |
| Dividends payments | - | - | - | - |
| Common Stock Repurchased | -10.7 Million | - | - | - |
| Common Stock Issuance | 16.65 Million | 1.86 Million | - | 3 Million |
| Other Financing Activities | -2.42 Million | 1865.38 | 10.46 Million | 3.24 Million |
| Accounts receivables | - | - | - | - |
| Accounts payables | 2.4 Million | 6.61 Million | -311.86 Thousand | -601.47 Thousand |
| Inventory | - | - | - | - |
| Other working capital | 194.5 Thousand | 1.67 Million | -708.45 Thousand | 3.71 Million |
| Cash at beginning of period | 5.9 Million | 328.58 Thousand | 174.67 Thousand | 724.42 Thousand |
| Cash at end of period | 3.13 Million | 699.32 Thousand | 328.58 Thousand | 174.67 Thousand |
| Capital Expenditure | -1.00 | - | - | - |
| Effect of forex changes on cash | - | - | - | - |
| Net cash flow / Change in cash | -2.76 Million | 370.74 Thousand | 153.91 Thousand | -549.75 Thousand |
| Free Cash Flow | -8.72 Million | -1.49 Million | -5.07 Million | -5.1 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -2.76 Million | -2.82 Million | -98.29 Million | -13.33 Million | -2.9 Million | -78.51 Million |
| Depreciation & Amortization | 2600.00 | 10.43 Thousand | 10.4 Thousand | 2600.00 | 2600.00 | 2600.00 |
| Deferred income taxes | 9707.00 | - | -9.47 Million | -596.06 Thousand | -485.00 | -7.83 Million |
| Stock-based compensation | 160.66 Thousand | 223.57 Thousand | 1.19 Million | 296.71 Thousand | 243.04 Thousand | 365.74 Thousand |
| Change in working capital | 676.68 Thousand | -1.26 Million | 2.6 Million | -1.4 Million | 1.69 Million | 2.61 Million |
| Other non-cash items | -22.89 Thousand | 627.48 Thousand | 95.25 Million | 12.24 Million | 22.81 Thousand | 82.95 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 2.67 Million | 5.95 Million | 4.34 Million | 2.28 Million | -641.76 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -10.7 Million | -1.00 | -230 Thousand | -10.47 Million |
| Common Stock Issuance | 79.19 Million | 2.67 Million | 16.65 Million | 4.34 Million | 2.09 Million | 395.2 Million |
| Other Financing Activities | - | 2.59 Billion | -2.42 Million | -653.51 Thousand | 417.36 Thousand | -385.36 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 188.76 Thousand | -303.83 Thousand | 2.4 Million | -465.95 Thousand | 753.5 Thousand | 1.76 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | 487.92 Thousand | -959.23 Thousand | 194.5 Thousand | -934.06 Thousand | 944.52 Thousand | 850.04 Thousand |
| Cash at beginning of period | 2.03 Million | 3.13 Million | 5.9 Million | 1.57 Million | 228.69 Thousand | 1.27 Million |
| Cash at end of period | 119.48 Thousand | 2.03 Million | 3.13 Million | 3.13 Million | 1.57 Million | 228.69 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -1.91 Million | -1.1 Million | -2.76 Million | 1.55 Million | 1.35 Million | -1.04 Million |
| Free Cash Flow | -1.91 Million | -3.77 Million | -8.72 Million | -2.78 Million | -936.39 Thousand | -407.62 Thousand |
VSEE
IDKOY
GVR
FFNT
MALEE
FEMY